Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 15 December 2007, Vol. 110, No. 13, pp. 4370-4372.
Prepublished online as a Blood First Edition Paper on October 1, 2007; DOI 10.1182/blood-2007-06-097014.

This Article
Right arrow Full Text (PDF)
Right arrow Supplemental Figure
Right arrow All Versions of this Article:
blood-2007-06-097014v1
110/13/4370    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oflazoglu, E.
Right arrow Articles by Gerber, H.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oflazoglu, E.
Right arrow Articles by Gerber, H.-P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Next Article next article arrow

Submitted June 27, 2007
Accepted September 21, 2007

Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30

Ezogelin Oflazoglu, Ivan J Stone, Kristine A Gordon, Iqbal S Grewal, Nico van Rooijen, Che-Leung Law, and Hans-Peter Gerber*

Department of Translational Biology, Seattle Genetics, Inc., Seattle, WA, United States
Department of Molecular Oncology and Immunology, Seattle Genetics, Inc., Seattle, WA, United States
Department of Preclinical Therapeutics, Seattle Genetics, Inc., Seattle, WA, United States
Department of Molecular Cell Biology, Vrije Universiteit, Amsterdam, Netherlands

* Corresponding author; email: hgerber{at}seagen.com.

Increased expression of CD30 is associated with a variety of hematologic malignancies, including Hodgkin's disease (HD) and anaplastic large cell lymphoma (ALCL). The anti-CD30 monoclonal antibody SGN-30 induces direct antitumor activity by promoting growth arrest and DNA fragmentation of CD30 positive tumor cells. In this study, we investigated the contributions of Fc-mediated effector cell functions to SGN-30 activity. We determined that antibody-dependent cellular phagocytosis (ADCP), mediated by macrophages, to contribute significantly to antitumor activity in vitro. To delineate the identity of the host effector cells involved in mediating anti-tumor activity in vivo, we studied the effects of effector cell ablation in a disseminated model of HD (L540cy). Depletion of macrophages markedly reduced efficacy of SGN-30 demonstrating that macrophages contribute significantly to SGN-30 efficacy in this model. These findings may have implications for patient stratification or combination treatment strategies in clinical trials conducted with SGN-30 in HD and ALCL.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Immunol.Home page
M. Leidi, E. Gotti, L. Bologna, E. Miranda, M. Rimoldi, A. Sica, M. Roncalli, G. A. Palumbo, M. Introna, and J. Golay
M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro
J. Immunol., April 1, 2009; 182(7): 4415 - 4422.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020